Here are three quick points:
1. Jeffries analysts reiterated their “buy” rating for NuVasive stock with a price target of $72, on July 27.
2. Barclays analysts reiterated their “overweight” rating for NuVasive shares with a price target of $71, on July 27.
3. On July 27, Brean Capital analysts reiterated their “buy” rating for NuVasive stock with a price target of $70.
More articles on devices:
DePuy Synthes, Acumed, Stryker market leaders in Japan device market: 5 takeaways
Medical device makers pivot towards value-based care: 7 thoughts
Orthogrid Systems offering outpatient and short-stay total joint surgeons complete control: 4 thoughts
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
